[email protected]

Redx Pharma appointed Dr Bernhard Kirschbaum to its Board as Non-Executive Director

– UK, Liverpool – Redx, the drug discovery and development company, is pleased to announce the appointment of Dr Bernhard Kirschbaum as Non-Executive Director, with effect from 1 January 2016.

Dr Kirschbaum, aged 57, has over 25 years’ experience in pharmaceutical research and drug development, predominantly at global pharmaceutical companies. During his career, he held leadership roles at Merck/Merck Serono, Sanofi-Aventis, Aventis and Hoechst Marion Roussel, and has expertise in a broad range of disease areas including oncology, immuno-oncology, immunology, neurological disorders and cardiometabolic diseases. Dr Kirschbaum’s experience also covers a wide range of technology areas across the spectrum of small molecules and biologics.

In the eight years to 2013, he worked at Merck/Merck Serono, based in Geneva, becoming a member of the Board of Merck Serono and Executive Vice-President, Global Research & Early Development. He was also responsible for a budget of 1 billion euros and a global team of over 2,500 associates. In his last three years at Merck Serono, he led the successful growth of the company’s R&D portfolio, with over 70 programs in research, and doubled the number of phase II assets in this period.

Dr Kirschbaum is currently a member of several boards and advisory boards, including BioMedX, a life science incubator in Heidelberg, Protagen Diagnostics, which develops diagnostic tools for some of the most severe autoimmune diseases, and OMEICOS Therapeutics, a biopharmaceutical company focused on cardiovascular diseases.

Neil Murray, Chief Executive of Redx, said: “We are delighted to welcome Bernd to the Board as a Non-Executive Director. He has an outstanding track record and I have no doubt that Redx will benefit from his significant commercial and scientific expertise. We look forward to working with him as we drive the Company’s next phase of growth.”

Dr Bernhard Kirschbaum, Non-Executive Director of Redx, said: “I am very pleased to be joining the Board of Redx as a Non-Executive director. I think that Redx is one of the UK’s most promising drug discovery companies operating in cancer, immunology and infection. Over a relatively short space of time, Redx has already established an extensive pipeline which has yielded a number of very exciting drug candidates in several disease areas.

“Redx has ambitious plans for growth and I look forward to contributing fully towards the ongoing development of the business.”

About Redx Pharma Plc

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 13 proprietary (patent‑protected) drug programs. Five programs have now achieved pre-clinical proof of concept, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.

- DisclaimerNews, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.

Comments are closed.